Treatment of Paediatric Pulmonary Hypertension
|
|
- Wilfrid Thomas
- 5 years ago
- Views:
Transcription
1 Treatment of Paediatric Pulmonary Hypertension Dunbar Ivy, MD The Children s Hospital Heart Institute University of Colorado School of Medicine 1
2 Disclosures I have the following financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in this CME activity: The University of Colorado contracts with Actelion, Bayer, Lilly, and United Therapeutics for which I am a consultant UC Contract: Steering Committee Actelion / Bayer / Lilly / United Therapeutics Funding from NIH / FDA I do intend to discuss an unapproved/investigative use of a commercial product/device in my presentation. 2
3 5 th WSPH: Screening/Diagnostic Algorithm for Suspected Pediatric PH/PAH Yes Normal Echo / CXR / ECG? PH unlikely No Echo indicates left heart etiology of PH? Yes Evaluate for left heart, valvular disease Yes but suspect sleep disordered breathing Polysomnography Selective pulmonary angiography No No PFTs normal other than low DLco? Chest CT normal? Yes V/Q scan normal or low probability? No Evaluate for parenchymal lung disease, connective tissue disease, neuromuscular disease, or chest wall/restrictive disease Adapted from: Ivy DD, et al. J Am Coll Cardiol. 2013;62:D117-D126.
4 Guidelines for PH Management in BPD Screening for PH by echocardiogram is recommended in infants with established BPD (class I, Level B) Evaluation and treatment of lung disease, including assessments for hypoxemia, aspiration, structural airways disease, and the need for changes in respiratory support, is recommended in infants with BPD and PH before initiation of PAH-targeted therapy (class I, Level B) Evaluation for chronic therapy for PH in infants with BPD should follow recommendations for all children with PH and include cardiac catheterization to diagnose disease severity and potential contributing factors such as LVDD, anatomic shunts, pulmonary vein stenosis, and systemic collaterals (class I, Level B) Supplemental oxygen therapy is reasonable to avoid episodic or sustained hypoxemia and with the goal of maintaining oxygen saturations between 92% and 95% in patients with established BPD and PH (class IIa, Level C) PAH-targeted therapy can be useful for infants with BPD and PH on optimal treatment of underlying respiratory and cardiac disease (class Ila, Level C) Abman SH, Hansmann G, Archer S, Ivy DD, et al. Circulation. 2015;132:
5 WSPH Consensus Pediatric IPAH/HPAH Treatment Algorithm * Expert Referral General: Consider Diuretics, Oxygen, Anticoagulation, Digoxin Acute Vasoreactivity Testing Oral CCB Positive + > 1 y.o. Lower Risk Negative Higher Risk - Improved - Sustained reactivity Yes Continue CCB No Modified from J Am Coll Cardiol. 2009;53: ERA or PDE-5i (oral) Iloprost (inhaled) Treprostinil (inhaled/oral) Selexipag (oral) Reassess consider early combo-therapy Epoprostenol or Treprostinil (IV/SQ) Consider Early Combination ERA or PDE-5i (oral) Atrial septostomy Lung transplant *Use of all agents is considered off label in children aside from sildenafil / bosentan formulation in EU /bosentan in US
6 6 Pulmonary Vascular Reactivity Testing Acute response Classic (REVEAL) - Decrease in mpap of at least 20% - with the PVR decreasing 20% - with no change or an increase in cardiac output Acute response -Sitbon - Decrease in mpap of at least 10 mmhg - with the mpap decreasing 40 mmhg - with a normal or high cardiac output
7 Idiopathic PAH in Children: Survival and Treatment Success with Chronic Oral CCB in Acute Responders Event Free Proportion Years after Diagnosis 7 Yung D, et al. Circulation 2004;110:
8 8 Responder Status and CCB Survival Douwes, JM, et.al. JACC 2016, Vol.67(11), p
9 Role of CCBs in PAH Patients with PAH should NOT be treated empirically with CCBs In patients with PAH with right heart failure, CCB therapy may worsen the heart failure Patients who fail to respond to acute vasodilator challenge should NOT be treated with CCBs Acute vasodilator challenge should be performed during right heart catheterization Use inhaled NO or IV epoprostenol for acute challenge
10 10 Safety, Efficacy and Dosing of the Following Medications is Not Yet Established in Pediatric Patients
11 Established vasomotor pathways targeted by current and emerging therapies in PAH ETB NO Humbert M et al. Circulation. 2014;130:
12 PAH-specific Treatment Options for Adults Failing Acute Vasoreactivity Testing Oral Therapy Inhaled Therapy Continuous Parenteral Therapy ERAs PDE5 Inhibitors sgc Stimulator Prostacyclin Prostacyclins Ambrisentan Sildenafil Riociguat Treprostinil Iloprost Epoprostenol (Flolan ) Bosentan Tadalafil Treprostinil RTS epoprostenol (Veletri ) Macitentan Treprostinil (SC or IV) Note: Only bosentan is FDA approved for use in pediatric patients over 3 years of age.
13 WSPH Consensus Pediatric IPAH/HPAH Treatment Algorithm Higher risk vs. Lower Risk Factors LOWER RISK DETERMINANTS OF RISK HIGHER RISK No Clinical evidence of RV failure Yes No Progression of Symptoms Yes No Syncope Yes Growth Failure to thrive I,II WHO Functional Class III,IV Minimally elevated SBNP / NTproBNP Significantly elevated Rising level Echocardiography Severe RV enlargement/dysfunction Pericardial Effusion Systemic CI > 3.0 L/min/m 2 mpap/msap < 0.75 Acute Vasoreactivity Hemodynamics Systemic CI < 2.5 L/min/m 2 mpap/msap > 0.75 RAP > 10mmHg PVRI > 20 WU*m 2 Ivy, et al. J Am Coll Cardiol. 2013;62:D117-26
14 WSPH Consensus Pediatric IPAH/HPAH Treatment Algorithm * Expert Referral General: Consider Diuretics, Oxygen, Anticoagulation, Digoxin Acute Vasoreactivity Testing Oral CCB Positive + > 1 y.o. Lower Risk Negative Higher Risk - Improved - Sustained reactivity Yes Continue CCB No Modified from J Am Coll Cardiol. 2009;53: ERA or PDE-5i (oral) Iloprost (inhaled) Treprostinil (inhaled/oral) Selexipag (oral) Reassess consider early combo-therapy Epoprostenol or Treprostinil (IV/SQ) Consider Early Combination ERA or PDE-5i (oral) Atrial septostomy Lung transplant *Use of all agents is considered off label in children aside from sildenafil / bosentan formulation in EU /bosentan in US
15 Endothelin Receptor Antagonists Generic Name Bosentan Ambrisentan Macitentan Selectivity ET A /ET B ET A ET A /ET B Trade Name Tracleer Letairis Opsummit Manufacturer Actelion Gilead Actelion Approval 2001 Sep 2017 Class III, IV II, III Indications (Package Insert) PAH WHO Group I PAH WHO Group I PAH WHO Group I Route Oral Oral Oral 15
16 FDA Approval of Bosentan in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability
17 BREATHE 3 : Study Design Screening Day 1 Hemodynamics Single-dose PK Week 12 Hemodynamics Multiple-dose PK Extended Open label Weight Group* Single dose PK Dose Target dose (4 weeks) x > 40 kg 125 mg 62.5 mg bid 125 mg bid 20 < x < 40 kg 62.5 mg mg bid 62.5 mg bid 10 < x < 20 kg mg mg qd mg bid Barst, et al. Clin Pharm Ther 2003 * + Flolan
18 BREATHE-3: Baseline Hemodynamics N=19 Patients kg Patients kg Patients >40 kg All PAPm (mm Hg) PVRI (Dyn.sec. m 2.cm -5 ) Cardiac Index (L/min/m 2 ) PCWPm (mm Hg) RAPm (mm Hg) mpap: mean pulmonary arterial pressure; PVRI: pulmonary vascular resistance index; mpcwp: mean pulmonary capillary wedge pressure; mrap: mean right atrial pressure Barst, et al. Clin Pharm Ther 2003
19 Table 3. Bosentan: Safety Beghetti, et al. Ped Res 2008:64:
20 Pulmonary arterial hypertension in children Protocol AC FUTURE 1 An open label, multicentre study to assess the pharmacokinetics, tolerability, and safety of a paediatric formulation of bosentan in children with idiopathic or familial pulmonary arterial hypertension
21 MACITENTAN VERSUS STANDARD OF CARE IN DELAYING DISEASE PROGRESSION IN CHILDREN WITH PULMONARY ARTERIAL HYPERTENSION: THE TOMORROW STUDY DESIGN
22 Clinical trials identifier: NCT TOMORROW study First randomized controlled pivotal study in children statistically powered to assess time to disease progression Primary objective Evaluate the efficacy of macitentan compared with standard of care in delaying disease progression in children with PAH Secondary objectives Assess safety and tolerability of macitentan in children with PAH Assess pharmacokinetics of macitentan in children with PAH
23 Clinical trials identifier: NCT Study design Event-driven, open-label study Randomization stratified for ERA & WHO FC Study schedule Screening 6 weeks PK visit Visits every 12 weeks EOS Follow-up 6 weeks Treatment arms Randomization (1:1) Macitentan (monotherapy or add-on to PDE-5i) SoC ( 2 PAH-specific treatments) 187 events: Study closure EOS, end of study; ERA, endothelin receptor antagonist; SoC, standard of care; WHO FC, World Health Organization functional class
24 Clinical trials identifier: NCT Disease progression: Composite endpoint Primary endpoint: Time to 1 st disease progression event up to EOS OR OR OR OR Death (all causes) Atrial septostomy or Pott's anastomosis Registration on lung transplant list Hospitalization due to PAH Clinical worsening of PAH Need for/initiation of new PAH-specific therapy or IV diuretics or continuous oxygen use AND Clinical worsening of PAH Characterized as: OR OR OR Worsening in WHO functional class Syncope (new/worsened) 2 PAH symptoms (new/worsened) Signs of RHF not responding to oral diuretics All events adjudicated by a blinded clinical events committee Shortness of breath/dyspnea, chest pain, cyanosis, dizziness/near syncope, or fatigue EOS, end of study
25 25 ETRA Interactions Contraindications: - Liver disease - Pregnancy - Cyclosporine - Risk of male infertility? Bosentan may decrease plasma sildenafil level by 60% Ambrisentan / Macitentan no effect on sildenafil or warfarin
26 Generic Name PDE5 Inhibitors Sildenafil Tadalafil Trade Name Revatio Cialis Manufacturer Pfizer Lilly Approval Class Indications (Package Insert) II,III, IV PAH WHO Group I PAH WHO Group I Route oral oral 26
27 STARTS-1 and -2 A randomized, double-blind, placebo controlled, dose ranging, parallel group study of oral sildenafil in the treatment of children, aged 1-17 years, with pulmonary arterial hypertension (PAH) Barst R, Ivy DD, et al. Circulation 2012;125:
28 STARTS-1: Placebo-adjusted Percent Change VO 2 Peak Low (n=24) Medium (n=26) High (n=27) Low/Med/High (n=77) p = VO 2 Peak (% change from baseline to Week 16) Comparison to Placebo (n=29) with 95% CIs Barst R, Ivy DD, et al. Circulation 2012;125:
29 Kaplan-Meier Estimated Survival From Start of Sildenafil Treatment in STARTS-1 and -2 94% 93% 88% Hazard ratios for mortality were 3.95 (95% CI, ) H vs L Barst RJ, et al. Circulation 2014;129:
30 Baseline Characteristics and Mortality 77% (30/39) of deaths were in IPAH children 77% (30/39) of the subjects who died had baseline PVRI to the median (15 Wood units x m2) 67% (26/39) had mpap to the median (62 mmhg) 72% (28/39) had RAP to the median (7.0 mmhg) Barst RJ, et al. Circulation 2014;129:
31 spap (mm Hg) spap/ssbp Sildenafil in Chronic Lung Disease of Infancy 120 Change in Systolic Pulmonary Artery Pressures in Response to Sildenafil p <0.001 p <0.001; T-test (n = 13) 1.4 Change in Systolic Pulmonary/Systemic Artery Pressure in Response to Sildenafil p <0.001; T-test (n = 13) Baseline After Sildenafil 0 Baseline After Sildenafil Median interval between studies: 58 days (25-334) Median interval between studies: 58 days (25-334) Mourani, Sontag, Ivy, Abman. J Peds 2009;154:
32 Oxyhemoglobin saturation (%) Mean PA pressure (mmhg) Sildenafil in Failing Fontan Physiology p= p= Pre Post 10.0 Pre Post Morchi, Ivy, Duster, et al. Congenit Heart Dis 2009;4:
33 33 Tadalafil in Pediatric PH 1. Protocol H6D-MC-LVHV A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension
34 Prostanoids Generic Name Epoprostenol Treprostinil Iloprost Trade Name Flolan Remodulin Ventavis Manufacturer GlaxoSmithKline United Therapeutics Actelion Approval (SQ) 2004 (IV) INH (Oral) 2004 Class III, IV II, III, IV III, IV Indications (Package Insert) PPH, SPH due to scleroderma PAH PAH WHO Group I Route Continuous IV Cont. SQ or IV Inhaled 34
35 Event Free Proportion Idiopathic PAH in Children: Survival and Treatment Success with Chronic IV Epoprostenol Years after Epoprostenol Initiation 35 Yung D, et al. Circulation 2004;110:
36 IV Treprostinil Administration Requires higher dose Longer half life: 3-4 hours Stable at room temp for 48 hrs for IV and 72 hrs for SQ No Ice Packs Every other day mixing
37
38 Oral Treprostinil Laser Drilled Hole Semi-permeable Membrane
39 Clinical Trial: Oral Treprostinil Multi-center, open-label, safety, tolerability and pharmacokinetic study of oral treprostinil in pediatric subjects with stable PAH aged 7 to 17 years who are, (1) transitioning from parenteral Remodulin therapy; (2) transitioning from inhaled prostacyclin therapy; or (3) not currently receiving prostacyclin therapy Primary Outcome Measures: Successful transition from parenteral Remodulin to oral treprostinil Cohort 1: A successful transition is defined as a subject who is receiving oral treprostinil and no longer receiving Remodulin at Week 4 and clinically maintained on oral treprostinil treatment through Week 24 Cohort 2 and 3: A successful initiation of oral treprostinil will be defined as a subject who has been clinically maintained on oral treprostinil through Week 24 Frequency of adverse events ClinicalTrials.gov Identifier: NCT
40 Oral Selexipag: Non-Prostanoid IP Receptor Agonist
41 Patent Child
42 Riociguat: PATENT Child 42
43 WSPH Consensus Pediatric IPAH/HPAH Treatment Algorithm * Expert Referral General: Consider Diuretics, Oxygen, Anticoagulation, Digoxin Acute Vasoreactivity Testing Oral CCB Positive + > 1 y.o. Lower Risk Negative Higher Risk - Improved - Sustained reactivity Yes Continue CCB No Modified from J Am Coll Cardiol. 2009;53: ERA or PDE-5i (oral) Iloprost (inhaled) Treprostinil (inhaled/oral) Selexipag (oral) Reassess consider early combo-therapy Epoprostenol or Treprostinil (IV/SQ) Consider Early Combination ERA or PDE-5i (oral) Atrial septostomy Lung transplant *Use of all agents is considered off label in children aside from sildenafil / bosentan formulation in EU /bosentan in US
44 Event-Free (%) Ambition: Time to First Clinical Failure Event Primary Analysis Set year 88.9% 2 year 79.7% 3 year 67.6% 50 1 year 75.5% 2 year 63.2% 3 year 56.1% Number at risk: 25 0 Combination therapy Pooled monotherapy Time (weeks) HR: % CI (0.348, 0.724) p= Combination: Pooled monotherapy: N Engl J Med 2015;373:
45 AMBITION: Initial Combination Therapy With Ambrisentan-Tadalafil Adverse Events Common Adverse Events (>=10%) Occurring with Higher Frequency in Combination Group (>=5% difference) by Etiology of PAH: Primary Analysis Set IPAH/HPAH APAH AE Term n, (%) Combination Therapy (n=134) Ambrisentan Monotherapy (n=75) Tadalafil Monotherapy (n=70) Any event 130 (97%) 71 (95%) 65 (93%) Edema peripheral 64 (48%) 23 (31%) 19 (27%) Headache 60 (45%) 24 (32%) 22 (31%) Nasal congestion 28 (21%) 12 (16%) 8 (11%) Dizziness 28 (21%) 10 (13%) 6 (9%) Nausea 23 (17%) 9 (12%) 8 (11%) AE Term n, (%) Combination Therapy (n=119) Ambrisentan Monotherapy (n=51) Tadalafil Monotherapy (n=51) Any event 117 (98%) 49 (96%) 49 (96%) Edema peripheral 51 (43%) 18 (35%) 15 (29%) Nasal congestion 26 (22%) 7 (14%) 7 (14%) Anemia 20 (17%) 2 (4%) 6 (12%) Bronchitis 15 (13%) 1 (2%) 2 (4%) Non-cardiac chest pain 13 (11%) 1 (2%) 3 (6%) Only adverse events with onset between first dose of study drug and last dose±30 days are tabulated 45
46 Drug Interactions 46
THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines
THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines Vu Nang Phuc, MD Dinh Duc Huy, MD Pham Nguyen Vinh, MD, PhD, FACC Tam Duc Cardiology Hospital Faculty Disclosure No conflict of interest
More informationPaediatric PAH in the current era
Paediatric PAH in the current era Dunbar Ivy, MD The Children s Hospital Heart Institute University of Colorado School of Medicine Paediatric PAH in the current era & A Gap Analysis Dunbar Ivy, MD The
More informationPharmacy Management Drug Policy
SUBJECT: Pulmonary Arterial Hypertension (PAH) POLICY NUMBER: Pharmacy-42 Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationCardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON
Cardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON Dunbar Ivy, MD The Children s s Hospital Heart Institute 1 Diagnostic Evaluation: Right Heart Cardiac
More informationSTARTS-1 and -2. Barst R, Ivy DD, et al. Circulation 2012;125:
STARTS-1 and -2 A randomized, double-blind,16 week placebo controlled, dose ranging, parallel group study of oral monotherapy sildenafil in treatment naive children, aged 1-17 years, with pulmonary arterial
More informationTherapeutic approaches in P(A)H and the new ESC Guidelines
Therapeutic approaches in P(A)H and the new ESC Guidelines Jean-Luc Vachiéry, FESC Head Pulmonary Vascular Diseases and Heart Failure Clinic Hôpital Universitaire Erasme Université Libre de Bruxelles Belgium
More information1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic
More informationIn focus The paediatric PAH population Clinicians Perspectives
In focus The paediatric PAH population Clinicians Perspectives Maurice Beghetti Pediatric Cardiology University Children s Hospital HUG and CHUV Pulmonary Hypertension Program HUG Centre Universitaire
More informationPULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Adcirca tadalafil Calendar Year Adempas riociguat Calendar Year Flolan epoprostenol sodium Calendar
More informationObjectives. Disclosures Oral Therapies for Children with Pulmonary Hypertensive Vascular Disease
Disclosures Oral Therapies for Children with Pulmonary Hypertensive Vascular Disease Erika Berman Rosenzweig, MD Director, Pulmonary Hypertension Center Associate Professor of Clinical Pediatrics (in Medicine)
More informationPulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University
Pulmonary Hypertension: When to Initiate Advanced Therapy Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Disclosures Medtronic, Abbott: Consultant Hemodynamic Definition of
More informationPulmonary arterial hypertension. Pulmonary arterial hypertension: newer therapies. Definition of PH 12/18/16. WHO Group classification of PH
Pulmonary arterial hypertension Pulmonary arterial hypertension: newer therapies Ramona L. Doyle, MD Clinical Professor of Medicine, UCSF Attending Physician UCSF PH Clinic Definition and classification
More informationTeaching Round Claudio Sartori
Teaching Round 14.03.2017 Claudio Sartori Cas clinique Femme 47 ans, connue pour un BPCO, asthénie, douleurs thoraciques, dyspnée à l effort, œdèmes membres inférieurs, deux syncopes. Tabac, BMI 31 kg/m2
More informationOral Therapies for Pulmonary Arterial Hypertension
Oral Therapies for Pulmonary Arterial Hypertension Leslie Wooten, PharmD PGY2 Internal Medicine Pharmacy Resident University of Cincinnati Medical Center April 30 th, 2018 Objectives Pharmacist Objectives
More informationClinical Policy: Macitentan (Opsumit) Reference Number: ERX.SPMN.88
Clinical Policy: (Opsumit) Reference Number: ERX.SPMN.88 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationPulmonary Arterial Hypertension: The Approach to Management in 2019
Pulmonary Arterial Hypertension: The Approach to Management in 2019 Munir S. Janmohamed M.D. FACC Medical Director Mechanical Circulatory Support/Heart Failure Program Mercy General Hospital/Mercy Medical
More informationProgress in PAH. Gerald Simonneau
Progress in PAH Gerald Simonneau National Reference center for Pulmonary Hypertension Bicetre University Hospital, INSERM U 999 Paris-Sud University Le Kremlin Bicêtre France Clinical Classification of
More informationPulmonary Hypertension in 2012
Pulmonary Hypertension in 2012 Evan Brittain, MD December 7, 2012 Kingston, Jamaica VanderbiltHeart.com Disclosures None VanderbiltHeart.com Outline Definition and Classification of PH Hemodynamics of
More informationPulmonary Hypertension: Another Use for Viagra
Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A
More informationDrug Class Monograph. Policy/Criteria:
Drug Class Monograph Class: Pulmonary Arterial Hypertension Agents Drugs: Adcirca (tadalafil), Adempas (riociguat), Flolan (epoprostenol), Letairis (ambrisentan), Opsumit (macitentan), Orenitram (treprostinil),
More informationADVANCED THERAPIES FOR PHARMACOLOGICAL TREATMENT OF PULMONARY HYPERTENSION
Status Active Medical and Behavioral Health Policy Section: Medicine Policy Number: II-107 Effective Date: 04/21/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
More informationPulmonary Arterial Hypertension Drug Prior Authorization Protocol
Pulmonary Arterial Hypertension Drug Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationReal-world experience with riociguat in CTEPH
Real-world experience with riociguat in CTEPH Matthias Held Center of Pulmonary Hypertension and Pulmonary Vascular Disease, Medical Mission Hospital, Würzburg, Germany Tuesday, 29 September ERS International
More informationThe Case of Marco Nazzareno Galiè, M.D.
The Case of Marco Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationIV PGI2 vs. Inhaled PGI2 in chronic lung disease
Inhaled Therapies for PAH Erika Berman Rosenzweig, MD Associate Professor of Clinical Pediatrics (in Medicine) Director, Pulmonary Hypertension Center Columbia University Medical Center Disclosures Has
More informationClinical Policy: Ambrisentan (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16
Clinical Policy: (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16 Last Review Date: 06/16 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationEffective Strategies and Clinical Updates in Pulmonary Arterial Hypertension
Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension Hap Farber Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures 1) Honoria: Actelion, Gilead,
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 4/19/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationRecent Treatment of Pulmonary Artery Hypertension. Cardiology Division Yonsei University College of Medicine
Recent Treatment of Pulmonary Artery Hypertension Cardiology Division Yonsei University College of Medicine Definition Raised Pulmonary arterial pressure (PAP) WHO criteria : spap>40 mmhg NIH Criteria
More informationAdvances in Pharmacotherapy of PAH
24 th Annual Advances in Heart Disease Advances in Pharmacotherapy of PAH Gabriel Gregoratos, MD 12/14/2007 UCSF Cardiology 1 Faculty Disclosure Statement for Gabriel Gregoratos, MD Nothing to disclose
More informationUpdates in Pulmonary Hypertension Pharmacotherapy. Ziad Sadik PharmD BCPS
Updates in Pulmonary Hypertension Pharmacotherapy Ziad Sadik PharmD BCPS Disclosure Information I have no financial relationship to disclose AND I will not discuss off label use and/or investigational
More informationACCP PAH Medical Therapy Guidelines: 2007 Update. David Badesch, MD University of Colorado School of Medicine Denver, CO
ACCP PAH Medical Therapy Guidelines: 2007 Update David Badesch, MD University of Colorado School of Medicine Denver, CO Disclosure of Commercial Interest Dr. Badesch has received grant/research support
More informationApproach to Pulmonary Hypertension in the Hospital
Approach to Pulmonary Hypertension in the Hospital Todd M Bull MD Professor of Medicine Director Pulmonary Vascular Disease Center Director Center for Lungs and Breathing Division of Pulmonary Sciences
More information22nd Annual Heart Failure 2018 an Update on Therapy. Pulmonary Arterial Hypertension: Contemporary Approach to Treatment
22nd Annual Heart Failure 2018 an Update on Therapy Pulmonary Arterial Hypertension: Contemporary Approach to Treatment Ronald J. Oudiz, MD, FACP, FACC, FCCP Professor of Medicine The David Geffen School
More informationMACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH)
MACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH) ORPHAN DRUG AND RARE DISEASE 11 MAY 2017 Catherine Lesage, MD, Pediatrics Program Head, Actelion Copyright AGENDA Pulmonary Arterial
More informationThe Case of Lucia Nazzareno Galiè, M.D.
The Case of Lucia Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationPULMONARY HYPERTENSION RESPIRATORY & CRITICAL CARE CONFERENCE APRIL 21, 2016 LAURA G. HOOPER
PULMONARY HYPERTENSION RESPIRATORY & CRITICAL CARE CONFERENCE APRIL 21, 2016 LAURA G. HOOPER OUTLINE Brief review of WHO Group Classification Scheme Subgroups we ll focus on: WHO Group I Pulmonary Arterial
More informationTherapy Update: ERAs. Review of Mechanism. Disclosure Statements. Outline. Disclosure: Research support from United Therapeutics
1 Therapy Update: ERAs Disclosure Statements Disclosure: Research support from United Therapeutics Most of the medications discussed in this presentation are off-label usage Nidhy Varghese, MD Pulmonary
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Adcirca) Reference Number: HIM.PA.SP23 Effective Date: 05/17 Last Review Date: Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder at
More informationCONUNDRUMS IN PULMONARY ARTERIAL HYPERTENSION
CONUNDRUMS IN PULMONARY ARTERIAL HYPERTENSION MOHAMMED RAFIQUE ESSOP MILPARK HOSPITAL and UNIVERSITY OF THE WITWATERSRAND POINTS FOR DISCUSSION What is the pathogenetic mechanism of PAH? Importance of
More informationRole of Combination PAH Therapies
Role of Combination PAH Therapies Ronald J. Oudiz, MD, FACP, FACC Associate Professor of Medicine, David Geffen School of Medicine at UCLA Director, Liu Center for Pulmonary Hypertension Los Angeles Biomedical
More informationPulmonary Hypertension. Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes
Pulmonary Hypertension Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes Pulmonary Arterial Hypertension Disease of small pulmonary arteries Characteristic changes Medial hypertrophy Intimal
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationUpdates on Pulmonary Hypertension Treatment
Updates on Pulmonary Hypertension Treatment Dane Mellgren, PharmD PGY-1 Pharmacy Practice Resident Hennepin County Medical Center 04/27/18 Disclosure I have no disclosures to be made regarding the content
More informationNational Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007
Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationClinical Policy: Bosentan (Tracleer) Reference Number: CP.PHAR.191
Clinical Policy: (Tracleer) Reference Number: CP.PHAR.191 Effective Date: 03/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationPulmonary Arterial Hypertension (PAH): Emerging Therapeutic Strategies
Pulmonary Arterial Hypertension (PAH): Emerging Therapeutic Strategies Nick H. Kim, M.D. Clinical Professor of Medicine Director, Pulmonary Vascular Medicine Clinical Service Chief, PCCSM La Jolla Pulmonary,
More informationClass Update with New Drug Evaluation: Drugs for Pulmonary Arterial Hypertension
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationManaging Multiple Oral Medications
Managing Multiple Oral Medications Chris Archer-Chicko, MSN, CRNP PENN Presbyterian Medical Center Arlene Schiro,, CRNP Massachusetts General Hospital Mary Bartlett, CRNP Winthrop University Hospital PH
More informationClinical Policy: Ambrisentan (Letairis) Reference Number: CP.PHAR.190
Clinical Policy: (Letairis) Reference Number: CP.PHAR.190 Effective Date: 03/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationUpdate in Pulmonary Arterial Hypertension
Update in Pulmonary Arterial Hypertension Michael J Sanley, MD April 12, 2018 Disclosures I have nothing to disclose 2 1 Case Presentation 67 yo male with atrial fibrillation, CLL on IVIG, presents with
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Draft remit / appraisal objective: Draft scope To appraise the clinical and cost effectiveness
More informationClinical Policy: Treprostinil (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date:
Clinical Policy: (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date: 07.01.16 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Treprostinil (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date:
Clinical Policy: (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date: 07.01.16 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 10/1/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationDisclosures. Inhaled Therapy in Pediatric Pulmonary Hypertension. Inhaled Prostacyclin: Rationale. Outline
Disclosures Inhaled Therapy in Pediatric Pulmonary Hypertension The University of Colorado receives fees for Dr Ivy to be a consultant for Actelion, Gilead, Lilly, Pfizer, and United Therapeutics Dunbar
More information4/14/2010. Pulmonary Hypertension: An Update. Tim Williamson, MD, FCCP. University of Kansas Hospital. Normal Physiology
Pulmonary Hypertension: An Update Tim Williamson, MD, FCCP Director, Pulmonary Vascular Program University of Kansas Hospital Normal Physiology 1 Pulmonary Perfusion 101 High Pressure Low Pressure Pulmonary
More information2015 State-of-the-Art Management of Pulmonary Hypertension Based on an Understanding of the Various Etiologies
2015 State-of-the-Art Management of Pulmonary Hypertension Based on an Understanding of the Various Etiologies Vallerie V. McLaughlin, MD, FACC, FAHA Kim A Eagle MD Endowed Professor of Cardiovascular
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Ambrisentan (Letairis) Reference Number: CP.PHAR.190 Effective Date: 07.01.18 Last Review Date: 01.12.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the
More informationSATELLITE SYMPOSIUM OF MSD. sgc Stimulation for the treatment of PH. Real life management of PAH: case presentation
SATELLITE SYMPOSIUM OF MSD sgc Stimulation for the treatment of PH Real life management of PAH: case presentation Eftychia Demerouti MD, MSc, PhD Cardiologist Onassis Cardiac Surgery Center Conflict of
More informationPharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications
Pharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications Effective: January 15, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tracleer) Reference Number: CP.PHAR.191 Effective Date: 03.16 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Opsumit) Reference Number: CP.PHAR.194 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Letairis) Reference Number: CP.PHAR.190 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace, Medicaid Revision Log See Important Reminder at the
More informationNational Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008
Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class April 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationIdentifying Appropriate Treatment & Management Strategies in Pulmonary Arterial Hypertension
Identifying Appropriate Treatment & Management Strategies in Pulmonary Arterial Hypertension Harold I. Palevsky, M.D. Perelman School of Medicine of the University of Pennsylvania Penn Presbyterian Medical
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Revatio) Reference Number: CP.PHAR.197 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2020-10 Program Prior Authorization/Medical Necessity PAH Agents Medication Adcirca (tadalafil), Adempas (riociguat), Letairis
More informationClinical Policy: Treprostinil (Orenitram, Remodulin, Tyvasco) Reference Number: CP.PHAR.199
Clinical Policy: (Orenitram, Remodulin, Tyvasco) Reference Number: CP.PHAR.199 Effective Date: 03/16 Last Review Date: 03/17 See Important Reminder at the end of this policy for important regulatory and
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Revatio) Reference Number: CP.PHAR.197 Effective Date: 03.16 Last Review Date: 02.19 Line of Business: Commercial, HIM*, Medicaid Revision Log See Important Reminder at the end of this
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tracleer) Reference Number: CP.PHAR.191 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Letairis) Reference Number: CP.PHAR.190 Effective Date: 03.16 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationPrior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
Pharmacy Medical Necessity Guidelines: Effective: July 11, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Flolan, Veletri) Reference Number: CP.PHAR.192 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder
More informationPulmonary Hypertension. Murali Chakinala, M.D. Washington University School of Medicine
Pulmonary Hypertension Murali Chakinala, M.D. Washington University School of Medicine Pulmonary Circulation Alveolar Capillary relationship Pulmonary Circulation High flow, low resistance PVR ~1/15 of
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationTREPROSTINIL Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650
Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650 SODIUM TREPROSTINIL TYVASO 36537 36539 36541 TREPROSTINIL ORENITRAM 40827 **Please use the criteria for the specific drug requested**
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Orenitram, Remodulin, Tyvaso) Reference Number: CP.PHAR.199 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Coding Implications
More informationEffects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 46, No. 4, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.01.066
More informationCoding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Orenitram, Remodulin, Tyvaso) Reference Number: CP.PHAR.199 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, HIM*, Medicaid Description (Orenitram, Remodulin,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Orenitram, Remodulin, Tyvaso) Reference Number: CP.PHAR.199 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, HIM*, Medicaid Coding Implications Revision Log
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Adcirca) Reference Number: CP.PHAR.198 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More information4/21/2018. The Role of Cardiac Catheterization in Pediatric PVD. The Role(s) of Cath in PVD. Pre Cath Management. Catheterization Mechanics in PVD
UCSF Pediatric Heart Center Benioff Children s Hospitals Oakland & San Francisco April 19, 2018 The Role of Cardiac Catheterization in Pediatric PVD Phillip Moore MD, MBA The Role(s) of Cath in PVD Diagnosis
More informationUntreated idiopathic pulmonary arterial hypertension
Congenital Heart Disease Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension Delphine Yung, MD; Allison C. Widlitz, MS, PA; Erika Berman Rosenzweig, MD; Diane Kerstein, MD; Greg Maislin,
More informationCoding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Ventavis) Reference Number: CP.PHAR.193 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Coding Implications Revision
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Treprostinil (Orenitram, Remodulin, Tyvaso) Reference Number: CP.PHAR.199 Effective Date: 07.01.18 Last Review Date: 01.12.18 Line of Business: Oregon Health Plan Coding Implications Revision
More informationDr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college
Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college PULMONARY HYPERTENSION Difficult to diagnose early Because Not detected during routine physical examination and Even in advanced cases symptoms
More informationAcute Vasodilator Testing in Pulmonary Hypertension: What, When, and How?
Acute Vasodilator Testing in Pulmonary Hypertension: What, When, and How? Teresa De Marco, MD University of California, San Francisco Disclosures: Grants/Research: United Therapeutics, Lung Biotechnology,
More informationPulmonary Hypertension: Clinical Features & Recent Advances
Pulmonary Hypertension: Clinical Features & Recent Advances Lisa J. Rose-Jones, MD Assistant Professor of Medicine, Division of Cardiology Advanced Heart Failure/Cardiac Transplantation & Pulmonary Hypertension
More informationClinical Policy: Tadalafil (Adcirca) Reference Number: CP.PHAR.198
Clinical Policy: (Adcirca) Reference Number: CP.PHAR.198 Effective Date: 03/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More information